Western Blotting (WB), ELISA, Immunofluorescence (IF)
Purification
FRMPD1 Antibody is affinity chromatography purified via peptide column.
Immunogen
FRMPD1 antibody was raised against a 15 amino acid synthetic peptide from near the carboxy terminus of human FRMPD1. The immunogen is located within amino acids 1330 - 1380 of FRMPD1.
FRMPD1
Reactivity: Human
WB, IF (cc), IF (p)
Host: Rabbit
Polyclonal
AbBy Fluor® 750
Application Notes
FRMPD1 antibody can be used for detection of FRMPD1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunoflourescence starting at 20 μ,g/mL. For immunofluorescence start at 5 μ,g/mL.
Antibody validated: Western Blot in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
FRMPD1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
FRMPD1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
FRMPD1
(FERM and PDZ Domain Containing 1 (FRMPD1))
FRMD2 antibody, BC031840 antibody, mKIAA0967 antibody, FERM and PDZ domain containing 1 antibody, FRMPD1 antibody, Frmpd1 antibody
Background
FRMPD1 Antibody: The FERM and PDZ domain containing (FRMPD) protein family consists of four proteins that contain a FERM (Four-point-one, erzin, radixin, moesin) domain and at least one PDZ (PSD-95/Discs large/Zonula-occuldens-1) domain. FRMPD1 was initially identified through a yeast two-hybrid screening with Activator of G-protein signaling 3 (AGS3), a protein that acts to stabilize the GDP-bound conformation of Gai, as the bait. FRMPD1 binds to the tetratricopeptide repeat of AGS3 and stabilizes AGS3 in a membrane environment. Suppression of FRMPD1 in Cath.a-differentiated neuronal cells decreased the level of endogenous AGS3 in membrane fractions by ~50 % and enhanced the inhibition of forskolin-induced increases in cAMP. Co-immunoprecipitation studies indicate that the interaction of AGS3 with FRMPD1 is mutually exclusive with the interaction of AGS3 with Gai3, suggesting that FRMPD1 may position AGS3 in the membrane where it can then interact with Galphai.